Extended-release ketamine tablets offer new hope for treatment-resistant depression

FHS
June 26, 2024
4:17 am

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

Exploring the link between sociocultural institutions and health in Asian and Hispanic neighborhoods

The number of sociocultural institutions within ethnic enclaves may play a significant role in positively influencing the health of immigrant Asian American and Hispanic populations,

August 9, 2024

Results from a nested randomized controlled trial for BCG vaccination against recurrent herpes labialis

Researchers examined the effect of Bacillus Calmette-Guérin (BCG) vaccination on attenuating herpes labialis (cold sore) recurrences.

September 14, 2023

AbbVie’s migraine medication Qulipta gets positive CHMP opinion – Pharmaceutical Technology

AbbVie’s Qulipta could bring relief to over 40 million migraine sufferers in Europe. Source: Shutterstock / Tunatura. AbbVie announced the European Medicines Agency’s (EMA) Committee

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.